Influence of thymectomy on the course of myasthenia gravis and the role of the surgical procedure

Influence of thymectomy on the course of myasthenia gravis and the role of the surgical procedure - MG-Thymectomy

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00035482

Enrollment

1950

Registered

2025-03-06

Start date

2025-01-28

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G70.0

Interventions

Group 1: Tmin: MG patients who underwent minimally invasive thymectomy Group 2: Toffen: MG patients who underwent an open thymectomy Group 3: T0: MG patients who did not undergo a thymectomy

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Confirmed diagnosis of MG - Capacity to consent and written informed consent of the patient - Minimally invasive thymectomy performed = 90 days ago (Tmin group) or open thymectomy = 90 (Toffen group) OR - No thymectomy (T0 group)

Exclusion criteria

Exclusion criteria: - Lack of communication skills

Design outcomes

Primary

Measure	Time frame
Survival time after 5 years	—

Secondary

Measure	Time frame
Taking steroid therapy (yes/no) Average daily steroid dose Use of long-term immunosuppression (includes use of azathioprine, mycophenolate mofetil, methotrexate, ciclosporin, rituximab, efgartigimod or ravulizumab) Use of exacerbation therapy [plasmapheresis / immunoadsorption / intravenous immunoglobulins (IVIG)] Myasthenia Gravis Activities of Daily Living (MG-ADL) scale Occurrence of a perioperative complication (e.g. injury to neighboring organs and structures, bleeding, etc.) New occurrence of other autoimmune diseases after thymectomy (e.g. systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), etc.).	—

Measure

Time frame

Taking steroid therapy (yes/no) Average daily steroid dose Use of long-term immunosuppression (includes use of azathioprine, mycophenolate mofetil, methotrexate, ciclosporin, rituximab, efgartigimod or ravulizumab) Use of exacerbation therapy [plasmapheresis / immunoadsorption / intravenous immunoglobulins (IVIG)] Myasthenia Gravis Activities of Daily Living (MG-ADL) scale Occurrence of a perioperative complication (e.g. injury to neighboring organs and structures, bleeding, etc.) New occurrence of other autoimmune diseases after thymectomy (e.g. systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), etc.).

—

Countries

Germany

Contacts

Public ContactFrauke Stascheit

Charité Universitätsmedizin Berlin

frauke.stascheit@charite.de+49 30 450 539723

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026